We are live on ! Find out more
BIS icon

ProShares UltraShort NASDAQ Biotechnology
BIS

4 hedge funds and large institutions have $283K invested in ProShares UltraShort NASDAQ Biotechnology in 2025 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

6.81% less ownership

Funds ownership: 12.11% → 5.3% (-6.8%)

48% less capital invested

Capital invested by funds: $542K → $283K (-$259K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$50.7K
2
Morgan Stanley
Morgan Stanley
New York
+$21

Top Sellers

Rank Fund Capital Flow
1
CAG
Csenge Advisory Group
Florida
-$163K
2
TRCT
Tower Research Capital (TRC)
New York
-$42.3K

BIS Hedge Fund Activity: Q4 2025 in Review

4 institutional investors reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2025, worth a combined $283K — down 48% from $542K a quarter earlier.

Fund positioning in BIS was balanced in Q4 2025: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $50.7K. The largest seller was Csenge Advisory Group, exiting entirely with an estimated $163K sold.

  • 4 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2025, unchanged from Q3 2025.
  • Funds reported $283K of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2025, down 48% quarter-over-quarter.
  • 1 fund opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2025 and 1 closed out, a net change of 0 holders.
  • The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2025 was Susquehanna International Group, an estimated $50.7K added.
  • The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2025 was Csenge Advisory Group, an estimated $163K sold.

Based on aggregated 13F filings for Q4 2025.